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Abstract
Purpose: Dose-volume consistency of the planning target volume (PTV) andrectum for the prostate intensity modulated radiotherapy (IMRT) and volumetricmodulated arc therapy (VMAT) plans were evaluated and compared. Dependencesof radiobiological parameters of the prostate and rectum on the PTV and rectalvolume were also investigated. Methods: From 40 prostate IMRT and 50 VMATpatients treated with the same prescription (78 Gy per 39 fractions) anddose-volume criteria in the inverse planning, the prostate tumour controlprobability (TCP), rectal equivalent uniform dose (EUD) and rectal normal tissuecomplication probability (NTCP) were calculated. The dose-volume consistency ofthe PTV and rectum, demonstrating the variability of dose-volume histogram(DVH) among patients, was defined and calculated as per the deviation betweenthe corresponding and mean DVH. Results: For the IMRT plans, the prostate TCPwas found increasing with the PTV with a rate equal to 1.05 × 10-3 % cm-3, whichwas lower than 1.11 × 10-3 % cm-3 for the VMAT plans. Both the rectal EUD andrectal NTCP were found decreasing with the rectal volume. The decrease rates forthe IMRT plans (EUD = 0.47 × 10-3 Gy cm-3 and NTCP = 3.94 × 10-2 % cm-3) werehigher than those for the VMAT (EUD = 0.28 × 10-3 Gy cm-3 and NTCP = 2.61 × 10-2% cm-3). Conclusion: For the dose-volume consistency, small prostate TCPvariation could be achieved by decreasing the dose-volume variability among theIMRT and VMAT plans. However, dependences of the rectal EUD and rectal NTCPon the dose-volume variability were not significant. It is concluded thatmaintaining a good dose-volume consistency in prostate plans can decrease theprostate TCP variation among the IMRT and VMAT patients. However, dose-volumevariability is not affected by variations of the rectal EUD and rectal NTCP.
Keywords: Prostate IMRT, Prostate VMAT, Dose-volume histogram, Prostate TCP,Rectal NTCP, Rectal EUD.
1. IntroductionIn external beam prostate cancer treatment, intensitymodulated radiotherapy (IMRT) has been widely used toreplace the 3D-conformal radiotherapy.1-4 Thestep-and-shoot IMRT used multiple static photon beamswith intensity modulated segmental fields to producehighly conformal dose coverage of the prostate planningtarget volume (PTV), while sparing the critical organsincluding the rectum, bladder and femoral head.5, 6Recently, volumetric modulated arc therapy (VMAT)becomes popular in prostate radiotherapy.7, 8 Instead of
sequencing a group of static beam segments producedby the multi-leaf collimator (MLC) in the IMRT, theVMAT technique employs a dynamic MLC approach,9 inwhich the MLC aperture, dose rate and gantry angle cansimultaneously be changing in a photon arc.10-12 Sinceonly one to two photon arcs typically are requiredinstead of multiple (5 – 9) photon beams in prostateradiotherapy, one fraction of VMAT can be deliveredfaster than that of IMRT.13, 14 However, since VMATdelivery interplays the MLC field, MLC leaf speed, dose
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rate and gantry speed in the treatment, more complexpatient specific quality assurance is needed.15, 16 For thedose distribution in treatment planning, studies showedthat prostate VMAT has comparable PTV dose coveragewith IMRT.17-19 Moreover, some studies found thatprostate VMAT has improved rectal, bladder andfemoral head sparing compared to IMRT.20-22To date, with the rapid development of treatmentplanning database and toolbox for plan evaluation,studies are conducted to investigate how the treatmentplanning quality assurance can be benefited by thepreviously treated plans using similar protocol anddelivery technique.23, 24 There are studies onknowledge-based planning methods that standardizingthe automatic radiation treatment plans with areduction of plan quality variability.25-27 Results of theabove studies lead to a developed model-basedtreatment planning methods that required inputs from apatient anatomy and prior treatment planningknowledge. In addition, the feasibility of using theknowledge-based planning database to adapt theprostate treatment plan from one institute to a set ofcases from an independent clinic was examined.27, 28 Theaim of using the knowledge-based planning model is todevelop a cross-institutional group that reduces thepoor systematic plan quality at institutions with limitedprostate IMRT/VMAT experience.Apart from using results from previously treated plansbased on the knowledge-based model, dose-volumeresults in treatment plans such as dose-volumehistograms (DVHs) from previously treated plans areused to compare with a new plan in quality assurance.24,
29 Dose-volume consistency in a prostate plan can bemaintained if the deviation of DVHs between the meancurve of the previously treated plans and the new plan issmall, indicating a low planning quality variability. Inthis case, the planning database is used to maintain adose-volume consistency in the treatment plan qualityassurance. So that every patient is treated with theexpected dose-volume characteristics based on the samedose delivery technique in the institution.28In this study, the dose-volume consistency in prostateradiotherapy was evaluated and compared between theIMRT and VMAT plans. Moreover, dependences of thedose-volume consistency on radiobiological parameterssuch as the prostate tumour control probability (TCP),rectal equivalent uniform dose (EUD) and rectal normaltissue complication probability (NTCP) were determinedand investigated. Relationships among the aboveradiobiological parameters, PTV and rectal volume werecompared between the IMRT and VMAT plans.
2. Methods and Materials
2.1. Patient dataForty and fifty prostate patients treated with IMRT andVMAT at the Grand River Regional Cancer Centre inGrand River Hospital were used in this study. Allpatients were treated with the same prescription dose(78 Gy in 39 fractions, 2 Gy per fraction) with no lymphnodes and semi-vesicle targeted.
2.2. Treatment planning and dose deliveryAll IMRT and VMAT treatment plans were created usingthe Pinnacle3 (Philips Medical Systems, Andover, MA)and Eclipse treatment planning system (Varian MedicalSystem, Palo Alto, CA). Dose delivery was carried out bya Varian 21 EX linear accelerator (Varian MedicalSystem, Palo Alto, CA) equipped with a 120-leafMillennium MLC system to generate beam segments forbeam intensity modulation. Patient specific dosimetryquality assurance measurements for the IMRT wereperformed by the MapCHECK® system (Sun NuclearCorp., Melbourne, FL), while for the VMAT wereperformed by the ArcCHECK® (Sun Nuclear Corp.,Melbourne, FL) and Delta4 system (ScandiDos Inc.,Madison, WI).For each patient in the IMRT or VMAT plan, the prostate,rectum, bladder, left and right femoral head werecontoured in his computed tomography (CT)-simulationimage set. The gross and clinical target volume (GTV andCTV) were equal to the prostate volume, while the PTVwas created by expansion of the CTV with 1 cm except0.7 cm posteriorly. Both IMRT and VMAT plans used thesame dose-volume criteria as shown in Table 1 in theinverse planning optimization. For the prostate IMRTplan, the seven-beam technique was used with beamenergy equal to 6 MV, and beam angles equal to 40o, 80o,110o, 250o, 280o, 310o and 355o. For the prostate VMATplan, a single 360o photon arc was used. The VMAT planwas inversely optimized by the Eclipse RapidArcalgorithm (Varian Medical System, Palo Alto, CA).
Table 1: Dose-volume criteria used in the IMRT and VMATprostate plans.Volume of interest Dose-volume criteria (Gy)CTV D99%  78PTV D99%  74.1PTV Maximum dose to 1 cm3 81.9Rectum D30%  70Rectum D50%  54.3Bladder D30%  70Bladder D50%  54.3Left and Right FemoralHead D5%  54.3
Volume 4 • Number 4 • 2016                                               International Journal of Cancer Therapy and Oncology 3
www.ijcto.org
© Chow et al. ISSN 2330-4049
2.3. Calculations of the prostate TCP, rectal EUD
and rectal NTCPThe prostate TCP was calculated by the followingequation:
exp( )      (1)1 exp( )
p qDTCP p qD
  
In this logistic regression equation, D is the dose.Parameters p and q are related to the D50 and thenormalized slope at the point of 50% control probability,
50. Information of D50 and 50 can be found from Okunieff
et al summarized related clinical data for a variety oftumours and reported parameters.30 From Eq. (1),control probability for the tumourlet, TCP(vi, Di), withvolume v and dose D can be inferred from the TCP forthe whole volume using the following equation:
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In Eq. (2), (vi, Di) represents the differential DVH.The phenomenological model suggested by Niemierkowas used to calculate the generalized EUD of therectum.31 The equation based on the power lawbehavior of tissue response is as follows:
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In Eq. (3), a is a biological parameter specified to anormal tissue. Parameter vi is the ith partial volumereceiving dose Di (Gy). Parameters a and vi have no unit.The Di and vi data pairs were determined from thedifferential DVH of the rectum. It should be noted thatthe sum of all partial volumes vi is equal to one becausethe relative volume of the whole volume of interest isequal to one. The value of a for rectum is set to 24 in thisstudy.32The rectal NTCP was calculated based on theLyman-Burman-Kutcher algorithm:33-35
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In Eq. (5), v = V/Vref and TD50 (v) = TD50 (1) v-n, assuggested by Burman et al,34 a TD50 of 80 Gy, an n of0.12, and m of 0.15 were used for rectum here. Theprostate TCP, rectal EUD and rectal NTCP weredetermined using an in-house program developed on theMATLAB platform by converting the cumulative DVH todifferential DVH.36
2.4. Estimation of the dose-volume consistencyThe consistency of the DVH is estimated by the followingequation:
1
1 ( ) ( )      (6)i in mean mean i ii v D v Dn  
where σ is the dose-volume variability based on the DVHrelative to its mean. vmean_i and Dmean_i are the relativevolume and dose data pairs of the mean DVH curve inthe database, while vi and Di are the corresponding datapairs of the DVH curve being estimated. n is the numberof dose bin in the DVH. It can be seen that when theestimated DVH curve is the same as the mean curve, σbecomes zero according to the Eq. (6), and there is nodose-volume variability in the target or normal tissue ofinterest.
3. ResultsFigures 1(a) and 1(b) show DVHs of the PTV and rectumfor all prostate IMRT patients, while Figures 2(a) and2(b) show DVHs of the PTV and rectum for all VMATpatients. In Figures 1 and 2, the corresponding meanDVH curves were calculated and are shown in red colorin the figures. The curves for the mean ± 2 × standarddeviation were also plotted and are shown in green andblue color in Figures 1 and 2. Dependence of theprostate TCP on the PTV is shown in Figure 3, whiledependences of the rectal EUD and rectal NTCP on therectal volume are shown in Figures 4(a) and 4(b). Forthe dose-volume consistency, dependence of theprostate TCP on the dose-volume variability is shown inFigure 5.  Figures 6(a) and 6(b) show dependences ofthe rectal EUD and rectal NTCP on the dose-volumevariability. All calculations in Figures 3 – 6 are based onone fraction of treatment dose equal to 2 Gy. Thestraight lines in Figures 3 and 4 are results of linearfitting according to the corresponding data points.
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a)
b)
Figure 1: DVHs of the PTV for all (a) IMRT and (b) VMAT prostate plans with the mean, mean + 2 × standard deviation,and mean - 2 × standard deviation curves in red, green and blue color, respectively.
Volume 4 • Number 4 • 2016                                               International Journal of Cancer Therapy and Oncology 5
www.ijcto.org
© Chow et al. ISSN 2330-4049
a)
b)
Figure 2: DVHs of the rectum for all (a) IMRT and (b) VMAT prostate plans with the mean, mean + 2 × standard deviation,and mean - 2 × standard deviation curves in red, green and blue color, respectively.
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(a)
b)
Figure 4: Rectal (a) EUD and (b) NTCP vs. rectal volume for all IMRT and VMAT plans.
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Figure 3: Relationship between the prostate TCP and PTV for all IMRT and VMAT plans.
Figure 5: Relationship between the prostate TCP and dose-volume variability for all IMRT and VMAT plans.
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a)
b)
Figure 6: Relationship between the rectal (a) EUD and (b) NTCP and the dose-volume variability for all IMRT and VMATplans.
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4. Discussion
4.1. DVHs of the PTV and rectumIn Figures 1(a) and 1(b), it is seen that most DVH curvesof the prostate PTV are within the mean DVH curve ± 2 ×standard deviation. For the mean DVH curves of the PTV,the D99%, D95% and D5% for the IMRT plans are 74.12 Gy,75.61 Gy and 81.25 Gy, which have no significantdeviation compared to those for the VMAT plans (D99%,D95% and D5% = 74.45 Gy, 76.25 Gy, and 81.45 Gy).Moreover, the mean dose of the PTV for the VMAT plansis 79.05 Gy which is slightly higher than that for theIMRT plans (78.63 Gy). In this study, all plans wereapproved based on the specific dose-volume criteria(Table 1) with patient specific dosimetry qualityassurance passed.For the DVH curves of the rectums in Figures 2(a) and2(b), the mean DVH curves for the IMRT and VMATplans are shown together with the curves ± 2 × standarddeviation. It can be seen that most DVH curves of therectums are enveloped between the mean curves ± 2 ×standard deviation. For the mean DVH curves of therectums, the D30% and D50% for the IMRT plans are 47.4Gy and 30.5 Gy, which are slightly higher than those forthe VMAT (D30% and D50% = 47.1 Gy and 27.9 Gy). TheV30Gy and V38Gy for the IMRT plans are also higher(62.44% and 51.4%) than those for the VMAT (56.7%and 47.8%), and the mean dose of the rectum is 35.27 Gyfor the IMRT plans compared to 33.91 Gy for the VMAT.
4.2. Dependences of the prostate TCP on the PTV,
and rectal EUD and rectal NTCP on the rectal
volumeFigure 3 shows the relationship between the prostateTCP and PTV for the IMRT and VMAT plans. In Figure 3,it can be seen that the prostate TCP slightly increaseswith the PTV for both the IMRT and VMAT plans.According to the slopes of lines in data fitting, the rate ofprostate TCP increased with PTV for the IMRT plans is1.05 × 10-3 % cm-3, compared to 1.11 × 10-3 % cm-3 forthe VMAT. Moreover, the mean prostate TCP for theVMAT plans is about 0.16 % higher than the IMRT. Thisindicates that slightly higher prostate TCP can beachieved by using the VMAT technique compared to theIMRT.Dependences of the rectal EUD on the rectal volume areshown in Figure 4(a) for the IMRT and VMAT plans. It isseen in Figure 4(a) that the rectal EUD of both the IMRTand VMAT plans decrease with an increase of the rectalvolume. From the straight lines plotted based on datafitting, slopes of lines for the IMRT and VMAT plans are0.47 × 10-3 Gy cm-3 and 0.28 × 10-3 Gy cm-3, respectively.That is, the variation of rectal EUD on the rectal volumeis more sensitive to the IMRT plans than the VMAT.Similar relationship can be found in Figure 4(b) showingthe dependences of the rectal NTCP on the rectalvolume. The rectal NTCP decreases with an increase of
rectal volume in a rate equal to 3.94 × 10-2 % cm-3 and2.61 × 10-2 % cm-3, for the IMRT and VMAT plans,respectively. Again, variation of the rectal NTCP on therectal volume is more sensitive to the IMRT plans thanthe VMAT.
4.3. Dependences of the prostate TCP, rectal EUD,
rectal NTCP on the dose-volume variabilityThe prostate TCP is plotted against the dose-volumevariability, σ calculated from the Eq. (6) based on DVHsof the PTV from the IMRT and VMAT plans, as shown inFigure 5. It is seen in Figure 5 that the prostate TCP forthe VMAT plans is higher than that of the IMRT, whichagrees with Figure 3. The mean prostate TCP for theIMRT plans is 95.61% which is lower than 95.76% forthe VMAT. When the value of σ is close to zero, whichmeans the dose-volume consistency is high, thevariation range of the prostate TCP is small. This revealsthat a high dose-volume consistency can ensure a smallprostate TCP variation in both the IMRT and VMATplans.Figures 6(a) and 6(b) show the dependences of therectal EUD and rectal NTCP on the dose-volumevariability for the IMRT and VMAT plans. In Figure 6, itis seen that though there is a slight increase of rectalEUD and rectal NTCP range with a decrease ofdose-volume consistency, the deviation of data betweenthe IMRT and VMAT plans is not significant. It is foundfrom the figure that the dependences of the rectal EUDand rectal NTCP on the dose-volume consistency arevery similar for the IMRT and VMAT plans. This showsthat both the IMRT and VMAT plans have similarvariations of the rectal EUD and rectal NTCP on thedose-volume consistency.
5. ConclusionDependences of dose-volume consistency on theprostate TCP, rectal EUD and rectal NTCP wereevaluated and compared between the IMRT and VMATplans. In addition, variations of the above radiobiologicalparameters on the PTV and rectal volume were studied.It is found that while the prostate TCP increased withthe PTV, the rectal EUD and rectal NTCP decreased withan increase of the rectal volume. The variation rates ofthe rectal EUD and rectal NTCP were higher for theIMRT plans than VMAT. For dependences of the prostatedose-volume consistency, it is concluded that a smallprostate TCP variation can be maintained by decreasingthe dose-volume variability. However, variations of therectal dose-volume consistency on the rectal EUD andrectal NTCP were found not significant for both theIMRT and VMAT plans.
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